Form 4: Globus Medical Director Lemaitre Granted Stock Options

Director Dan Lemaitre of Globus Medical Inc. was granted stock options for 15,000 shares of Class A Common Stock on January 23, 2025.

Summary

• Dan Lemaitre, a director of Globus Medical Inc., received stock options to purchase 15,000 shares of Class A Common Stock.
• The options were granted on January 23, 2025, and have an exercise price of $92.42.
• The options will vest on January 1, 2026, and expire on January 23, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather an incentive mechanism.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Comparing the size and vesting schedule of this grant to those of directors at similar-sized medical device companies (e.g., NuVasive, Stryker, Medtronic) would provide context on its relative value and incentive structure.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to improve company performance, benefiting shareholders.

Key Dates

Keywords

stock options, Globus Medical, GMED, director, Dan Lemaitre, Class A Common Stock, insider trading, Form 4